Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Montazeri K, Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020 Jan; 13(1):1-6.
-
Sonpavde G, Sjödahl G. Erdafitinib in Urothelial Carcinoma. N Engl J Med. 2019 10 17; 381(16):1594.
-
Grivas P, DerSarkissian M, Shenolikar R, Laliberté F, Doleh Y, Duh MS. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA. Future Oncol. 2019 Nov; 15(33):3809-3818.
-
McGregor BA, Sonpavde G. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. Expert Opin Investig Drugs. 2019 Oct; 28(10):821-826.
-
Alston ELJ, Zynger DL. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ? Diagn Pathol. 2019 Aug 16; 14(1):91.
-
Badin J, Abello A, Gupta M, Das AK. Urothelial Carcinoma of the Bladder With a Rare Solitary Metastasis to the Ovary. Urology. 2020 Jan; 135:24-27.
-
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
-
Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Arch. 2019 Oct; 475(4):445-455.
-
Gevaert T, Cimadamore A, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncol. 2019 Jul; 15(19):2199-2202.
-
Wu S, Lin SX, Lu M, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL. Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy. Int Urol Nephrol. 2019 Sep; 51(9):1527-1535.